Normal BMI and lower HbA1C increase hypoglycemia risk in Type 2 Diabetes patients on once-weekly semaglutide

Managing Type 2 Diabetes Mellitus (T2DM) often involves GLP-1 receptor agonists like semaglutide once-weekly injection (Sema-OWI), which effectively improves glycemic control and aids weight loss. However, hypoglycemia, a potentially dangerous side effect, remains a significant concern for healthcare providers. Identifying specific patient characteristics that predispose individuals to hypoglycemia while on semaglutide is crucial for optimizing treatment strategies and enhancing patient safety, as current understanding of these risk factors is not fully established.

Researchers conducted a matched case-control study with a 1:4 (case:control) ratio to identify risk factors for hypoglycemia in T2DM patients on sema-OWI. The study recruited 45 cases diagnosed with a hypoglycemic event and 180 controls without such events. Initial analysis used univariable conditional logistic regression to assess associations between patient characteristics and hypoglycemia, yielding matched odds ratios (mOR). Subsequently, multivariable conditional logistic regression was performed, adjusting for confounders like the number of T2DM medications and sema-OWI duration, to confirm independent predictors including body mass index (BMI) and glycosylated hemoglobin (HbA1C).

Univariable conditional logistic regression revealed several factors associated with a lower likelihood of hypoglycemia. Patients treated with sema-OWI for 4-6 months (mOR = 0.052; p<0.001) and more than 6 months (mOR = 0.045; p = 0.001) were significantly less likely to experience hypoglycemia. Similarly, obese patients (mOR = 0.110; p = 0.041) and those with an HbA1C level >9 (mOR = 0.254; p < 0.001) also showed a reduced risk. The multivariable conditional logistic regression analysis, adjusted for the number of T2DM medications and sema-OWI duration, confirmed these findings, establishing that obesity and higher HbA1C levels (>9) were associated with a lower likelihood of hypoglycemia. Conversely, this implies that patients with normal BMI and lower HbA1C levels (<7) were associated with a higher likelihood of hypoglycemia. This suggests that the duration of semaglutide treatment beyond 4 months may also reduce hypoglycemia risk. Overall, the study identified specific patient profiles that warrant closer monitoring for hypoglycemic events.

Normal body mass index and lower HbA1C levels (<7) were significantly associated with a higher likelihood of hypoglycemia in Type 2 Diabetes Mellitus patients treated with semaglutide once-weekly.